WebDec 17, 2024 · Updated results from the FIGHT-202 study supported the primary data that second-line pemigatinib treatment resulted in efficacy and sustained tolerability in … WebOct 5, 2016 · A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically …
FDA Approves Pemazyre as First Targeted Therapy …
WebApr 12, 2024 · Hollebecque A, Silverman I, Owens S, et al. Comprehensive genomic profiling and clinical outcomes in patients (pts) with fibroblast growth factor receptor … WebAmong these treatments, the fibroblast growth factor receptor (FGFR) 2 inhibitor pemigatinib has received accelerated approval in April 2024 by the US Food and Drug Administration (FDA) in CCA patients harboring FGFR2 gene fusions or other rearrangements, on the basis of the results of the FIGHT-202 trial, and thus, representing the first ... tari baris memedi
Updated Results of the FIGHT-202 Study Reinforced the Efficacy …
WebProgression-free survival (or PFS) was a secondary endpoint in the FIGHT-202 study. In FIGHT-202, the median PFS was 6.9 months. Overall survival (or OS) was also a secondary endpoint in FIGHT-202. Median OS was 21 months. Median follow-up at time of data cutoff was 15.4 months. The overall survival data were not mature at the data cutoff. WebJun 15, 2024 · Ghassan K. Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the updated results from the FIGHT-202 trial (NCT02924376): a Phas... WebAug 19, 2016 · A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. 風邪 ゼリー飲料